Alpha4beta7 and IL-23 Inhibitor Combination for IBD Remission

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for inflammatory bowel disease (IBD) have limitations in improving remission rates and modifying disease progression, highlighting an unmet medical need for alternative treatments that can effectively mitigate the disease burden.

Innovation Solution

A combination therapy involving an α4β7 inhibitor, such as an anti-α4β7 antibody like vedolizumab, and an IL-23 inhibitor, such as an anti-IL-23 antibody, is administered to patients with IBD, with specific dosing regimens and administration routes to target the immune response and reduce inflammation in the gut.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current single-agent therapies are used for IBD, then treatment simplicity is maintained, but remission rates and disease modification are insufficient

Engineering Contradiction:

Improveremission rateVSAvoidtherapy complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines two distinct therapeutic agents (α4β7 inhibitor and IL-23 inhibitor) into a single combination therapy regimen. This merging of multiple mechanisms of action addresses the insufficient remission rates of single-agent therapies while managing complexity through coordinated administration protocols

Inventive Principle:

Principle #5Merging (Combining)

2Object-affected harmful factors

If combination therapy with multiple agents is administered, then disease burden and inflammation are reduced, but treatment complexity increases

Engineering Contradiction:

Improveinflammation levelVSAvoidtreatment regimen complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The combination therapy is segmented into distinct dosing phases: an induction phase with specific dosing frequencies to rapidly reduce inflammation, followed by a maintenance phase with adjusted dosing to sustain remission. This segmentation manages treatment complexity by structuring the multi-agent regimen into manageable temporal stages with different objectives

Inventive Principle:

Principle #1Segmentation

Data Source

PatentUS20230096620A1Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Publication Date: 2023.03.30 TAKEDA PHARMA CO LTD

AI summary

Provided herein are combination therapies comprising an alpha4beta7 inhibitor, e.g., an anti-alpha4beta7 antibody, e.g., vedolizumab, and an IL-23 inhibitor, e.g., an anti-IL-23 antibody.